@inproceedings{inproceedings, title  = {{3-year safety follow-up of radium-223 dichloride (Ra-223) in patients (Pts) with castration resistant prostate cancer (CRPC) and symptomatic bone metastases (Mets) from ALSYMPCA}},

 url = {{}},

 year = {{2015}},

 month = {{10}},

 author = {{Amadori D and Rossetti C and Aglietta M and Messina C and Versari A and Vogelzang NJ and Sartor A and Coleman RE and Govi S and Fang F and Skjorestad I et al}},

 volume = {{26}},

 journal = {{ANNALS OF ONCOLOGY}},

 pages = {{55-55}},

 note = {{Accessed on 2025/10/10}}}